Ignite Creation Date:
2025-12-24 @ 2:41 PM
Ignite Modification Date:
2026-02-07 @ 6:16 PM
Study NCT ID:
NCT01180959
Status:
COMPLETED
Last Update Posted:
2022-11-07
First Post:
2010-08-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Sponsor:
Organization: